Bacteria therapy for eczema shows promise in new study

May 3, 2018, NIH/National Institute of Allergy and Infectious Diseases
A scientist demonstrates application of the experimental therapy to the inner elbow. For demonstration purposes, the bacteria solution has been replaced with purple dye. Credit: NIAID

Topical treatment with live Roseomonas mucosa—a bacterium naturally present on the skin—was safe for adults and children with atopic dermatitis (eczema) and was associated with reduced disease severity, according to initial findings from an ongoing early-phase clinical trial at the National Institutes of Health. Preclinical work in a mouse model of atopic dermatitis had suggested that R. mucosa strains collected from healthy skin can relieve disease symptoms. The new findings, published May 3 in JCI Insight, support further evaluation of this potential new therapy.

Atopic dermatitis is an inflammatory disease that can make skin dry and itchy, cause rashes and lead to skin infections. The disease is linked to an increased risk of developing asthma, hay fever and food allergy. Atopic dermatitis is common in children and sometimes resolves on its own, but it also can persist into or develop during adulthood.

"Living with can be physically and emotionally challenging. While can help manage the symptoms, currently available therapies can be time-consuming—requiring multiple daily applications—and costly," said Anthony S. Fauci, M.D., director of NIH's National Institute of Allergy and Infectious Diseases (NIAID). "New, inexpensive therapies that require less frequent application are needed to expand the options available for dermatitis treatment."

The cause of atopic dermatitis is unknown, but studies suggest that the skin microbiome—the community of bacteria and other microbes living on the skin—plays a key role. For years, scientists have known that people with atopic dermatitis tend to have large populations of Staphylococcus aureus bacteria on their skin. These bacteria can cause skin infections and trigger immune responses that increase inflammation and worsen symptoms.

Recent work by NIAID researchers using mouse and cell culture models of atopic dermatitis revealed that treatment with isolates of R. mucosa collected from the skin of healthy people improved disease outcomes in the models. In contrast, R. mucosa isolates from people with atopic dermatitis either had no impact or worsened outcomes in the models.

Based on these preclinical findings, NIAID investigators designed an early stage clinical trial to test the safety and potential benefit of a treatment containing live R. mucosa in people with atopic dermatitis. The Phase 1/2 study is being conducted at the NIH Clinical Center in Bethesda, Maryland.

"By applying bacteria from a healthy source to the skin of people with atopic dermatitis, we aim to alter the skin microbiome in a way that will relieve symptoms and free people from the burden of constant treatment," said NIAID's Ian Myles, M.D., the principal investigator of the trial. "If future clinical studies demonstrate that this strategy is effective, we hope our work will lead to development of new, low-cost atopic dermatitis therapies that do not require daily application."

The researchers first tested the experimental treatment in 10 adult volunteers with atopic dermatitis. Twice a week for six weeks, the volunteers sprayed a solution of sugar water containing increasing doses of live R. mucosa onto their inner elbows and one additional skin area of their choice. The R. mucosa strains included in the treatment were originally isolated from the skin of healthy individuals and grown under carefully controlled laboratory conditions. Participants were instructed to continue their normal eczema treatments, including topical steroids and other medications.

Participants did not report any adverse reactions or complications. Most participants experienced improvements in their atopic dermatitis, and four weeks after stopping the bacteria therapy, some reported needing fewer topical steroids.

The investigators next enrolled five volunteers aged 9 to 14 years with atopic dermatitis. Treatments were applied to all affected skin areas twice weekly for 12 weeks and every other day for an additional four weeks. Consistent with the findings in adults, there were no complications or adverse effects, and most participants experienced improvements in their eczema, including a reduced need for topical steroids. The researchers also found that treatment was associated with decreases in the S. aureus population on the children's skin.

Although larger studies comparing the bacteria therapy with a placebo will be required to assess the effectiveness of this potential treatment, the investigators observed a greater than 50 percent improvement in atopic dermatitis severity in four of the five children and six of the 10 adults. The researchers are continuing to monitor the five children who received treatment and are enrolling additional children into the study.

To better understand factors that may contribute to imbalances in the bacteria on the skin, the scientists also investigated whether chemicals produced by R. mucosa or present in certain skin products may be associated with atopic dermatitis. They found that strains of R. mucosa from people with atopic dermatitis produced skin irritants, while strains isolated from healthy skin produced chemicals that may enhance the skin's barrier and help regulate the immune system. In addition, some forms of parabens—a common preservative in skin products—and some topical emollients (moisturizers) blocked the growth of R. mucosa from healthy skin and did not have as strong an effect on growth of S. aureus or eczema-associated R. mucosa. These findings suggest that certain products may worsen atopic dermatitis and/or affect the effectiveness of microbiome-based therapies.

Final results from the ongoing study at NIH will provide the foundation for larger trials to evaluate the efficacy of this novel investigational therapy, as well as to better understand the role of R. mucosa in atopic dermatitis. NIH has exclusively licensed the technology to Forte Biosciences to advance this potential new therapy through further clinical development.

Explore further: Efficacy of wet wrap therapy for atopic dermatitis undetermined

More information: Ian A. Myles et al, First-in-human topical microbiome transplantation with Roseomonas mucosa for atopic dermatitis, JCI Insight (2018). DOI: 10.1172/jci.insight.120608

Related Stories

Efficacy of wet wrap therapy for atopic dermatitis undetermined

November 14, 2016
(HealthDay)—Evidence that wet wrap therapy (WWT) is more effective than topical steroids for the treatment of atopic dermatitis is mixed, according to a review published online Nov. 8 in the British Journal of Dermatology.

People susceptible to atopic dermatitis have different microbes living on their skin than non-sufferers

July 27, 2016
Microbial communities living on the skin of people susceptible to the skin disease atopic dermatitis differ from those of healthy individuals. This finding by A*STAR researchers provides insight into the roles that resident ...

Phthalate, paraben levels up in children with atopic dermatitis

March 21, 2017
(HealthDay)—Children aged 4 to 9 years with atopic dermatitis and with frequent use of emollients have increased urinary levels of low-molecular weight (LMW) phthalate metabolites and parabens, according to a study published ...

Researchers discover key driver of atopic dermatitis

January 17, 2018
Severe eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition that is driven by an allergic reaction. In their latest study, researchers at La Jolla Institute reveal an important player that promotes ...

How the skin becomes inflamed

November 8, 2017
Publishing online this week in Cell Host & Microbe, researchers at Johns Hopkins report the discovery of a key underlying immune mechanism that explains why to how our skin becomes inflamed from conditions such as atopic ...

Countering atopic dermatitis immune reactions

August 4, 2017
Human leukocyte antigen (HLA)-G is a protein that interacts with specific cell receptors to inhibit immune responses. The protein is best known for its role in protecting the fetus from attack by its mother's immune system. ...

Recommended for you

A Trojan Horse delivery for treating a rare, potentially deadly, blood-clotting disorder

September 21, 2018
In proof-of-concept experiments, University of Alabama at Birmingham researchers have highlighted a potential therapy for a rare but potentially deadly blood-clotting disorder, TTP. The researchers deliver this therapeutic ...

Study shows surprise low-level ozone impact on asthma patients

September 21, 2018
A new study led by UNC School of Medicine researchers indicates that ozone has a greater impact on asthma patients than previously thought. The study, published in the Journal of Allergy and Clinical Immunology, recruited ...

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

Gut fungus exacerbates asthma in antibiotic-treated mice

September 20, 2018
A non-pathogenic fungus can expand in the intestines of antibiotic-treated mice and enhance the severity of allergic airways disease, according to a study published September 20 in the open-access journal PLOS Pathogens by ...

Paracetamol use in infancy is linked to increased risk of asthma in some teenagers

September 17, 2018
Children who take paracetamol during their first two years of life may be at a higher risk of developing asthma by the age of 18, especially if they have a particular genetic makeup, according to new research presented at ...

Cord blood clue to respiratory diseases

September 15, 2018
New research has found children born in the last three months of the year in Melbourne may have a greater risk of developing respiratory diseases such as asthma.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.